Work

KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx377.042

Authors: M.B. Atkins, M.S. Carlino, A.G. Hill, C.M. McNeil, A. Ribas, V. Atkinson, J.S. Cebon, M.B. Jameson, W.-J. Hwu, J.A. Thompson, J. Anderson, B. Homet Moreno, N. Ibrahim, G.V. Long

Institutions: Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, The University of Sydney, Melanoma Institute Australia, Royal Prince Alfred Hospital, Chris O’Brien Lifehouse, University of California, Los Angeles, Greenslopes Private Hospital, Gallipoli Medical Research Foundation, Olivia Newton-John Cancer Wellness & Research Centre, Olivia Newton-John Cancer Research Institute, Waikato Hospital, The University of Texas MD Anderson Cancer Center, Seattle Cancer Care Alliance, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal North Shore Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2764080191

FWCI:

Cites:

Cited by:

Related to: 10